Copyright: ©Author(s) 2026.
World J Nephrol. Mar 25, 2026; 15(1): 115933
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115933
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115933
Table 5 Clinical outcome of the overall sample and stratified by finerenone dosage, n (%)
| All (n = 347) | Dosage 10 (n = 194) | Dosage 20 (n = 153) | P value | |
| Required RRT | 10 (2.9) | 8 (4.1) | 2 (1.3) | 0.0800 |
| Hyperkalemia | 44 (12.7) | 38 (19.6) | 6 (3.9) | 0.0000 |
| Suspended treatment | 13 (3.8) | 11 (5.7) | 2 (1.3) | 0.0335 |
| Suspended due to hyperkalemia | 4 (1.2) | 4 (2.1) | 0 (0.0) | 0.1333 |
- Citation: Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933
- URL: https://www.wjgnet.com/2220-6124/full/v15/i1/115933.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i1.115933